

# Global Lyme Disease Pandemia Overview

*Teaser, 2023*

# Table of Contents

<b>Introduction</b>	<b>2</b>
<b>Executive Summary</b>	<b>3</b>
<b>Link Between Lyme, Autism and Alzheimer</b>	<b>4</b>
<b>Significance of Lyme Pandemic as a Global Health Challenge</b>	<b>5</b>
<b>Key Global Findings</b>	<b>6</b>
<b>Geography of Clinical Trials, 2023</b>	<b>7</b>
<b>Billionaires affected by Lyme disease</b>	<b>8</b>
<b>Involvement of Celebrities in Lyme Awareness</b>	<b>9</b>
<b>Market at a Glance: Lyme Clinics</b>	<b>10</b>
<b>Lyme Industry Framework</b>	<b>11</b>
<b>Lyme Disease Diagnostic Market Size</b>	<b>12</b>
<b>Prospective Treatments for Lyme Disease</b>	<b>13</b>
<b>Lyme Disease Treatment Market Size</b>	<b>14</b>
<b>Conclusions</b>	<b>15</b>
<b>Longevity Industry Analytics: Value Proposition</b>	<b>16</b>
<b>Longevity Industry Analytics (LIA) Disclaimer.</b>	<b>17</b>

## Introduction

Aging Analytics Agency and Deep Knowledge Group have released a new report titled “Global Lyme Disease Pandemia Overview 2023” which examines the intricate landscape of Lyme disease, shedding light on its global ramifications and industry intricacies.

From unraveling the significance of Lyme as a pervasive health challenge to exploring its interplay with Autism and Alzheimer's, we delve into the latest scientific insights, epidemiological data, and the profound impact on public health. The scrutiny extends to the Lyme industry, providing an overview of key players, stakeholder collaborations, and market trends.


The report delves into the challenges and opportunities within Lyme diagnosis and treatment, foreseeing future regulatory considerations. Celebrity involvement, parliamentary initiatives, and the imperative for collaborative efforts are essential components of this comprehensive exploration.

## Executive Summary

Lyme disease, or Lyme, is a persistent condition marked by elevated **Borrelia burgdorferi bacteria** levels in the bloodstream, resulting in prolonged symptoms. Global shifts in outdoor activities, urbanization, and climate changes have transformed patterns of Lyme disease transmission. Traditional outdoor lifestyles have given way to modern routines, increasing exposure to ticks carrying Lyme-causing bacteria.

Tick-borne Lyme disease is becoming more common, and a study suggests that **more than 1 in 7 people worldwide** are currently infected or have previously had this illness. Understanding factors influencing Lyme prevalence is crucial for effective prevention, diagnosis, and management. Ongoing research, public awareness, and collaboration play pivotal roles in mitigating Lyme disease Global Health Impact.

## Prevalence of Lyme Disease



# Link Between Lyme, Autism and Alzheimer

## Understanding Age-Specific and Groups Impact

### Adults

Neurological Implications, Inflammatory Response

### Kids

Maternal Transmission, Inflammatory Impact

### Seniors

Age-Related Vulnerabilities, Inflammatory Response

### Animals


Neurological Concerns, Inflammatory Response

Lyme is a chronic health condition manifests unique neurological implications across age groups, with notable associations to **Autism in children** and **Alzheimer's in seniors**. Scientific endeavors aim to unravel the molecular pathways connecting Lyme disease to the development of Autism in children and Alzheimer's in seniors. Research delves into the complexities of how Lyme-induced factors may influence neurodevelopment in children and contribute to neurodegeneration in seniors.

Case studies provide insights into the intricacies of the link, offering valuable **perspectives on diagnosis, prevention, and potential interventions**. As we navigate through this report, we will explore the age-specific nuances of the link between Lyme disease and neurological conditions, shedding light on the complexities and implications for different age groups.

# Significance of Lyme Pandemic as a Global Health Challenge

Number of articles on Lyme Disease, 2000-2023




**More than 14% of the world's population** probably has, or has had, tick-borne Lyme disease, as indicated by the presence of antibodies in the blood. Lyme disease affects millions worldwide, posing a significant health challenge.

**Escalating incidence** demands heightened awareness and strategic interventions. Lyme Disease diverse manifestations strain healthcare systems globally.

**Links to Autism and Alzheimer's** amplify the challenge. Global collaboration needed for effective prevention and management.


## Key Global Findings



As of 2023, the global population has reached 8.14 billion. Approximately 14% of this population, which equates to 1.1376 billion people, is estimated to be affected by Lyme disease. This means that, statistically, roughly one in every seven individuals is grappling with Lyme. However, unofficial statistics suggest that the actual number could be three times higher, emphasizing the pervasive nature of Lyme disease and its classification as a global pandemic. All of these despite the fact, that there is more than \$1.3B of healthcare expenditure for Lyme treatment.

# Geography of Clinical Trials, 2023

## Countries by Number of Clinical Trials for Lyme Disease




**105** clinical trials were conducted on Lyme Disease in the world.

USA is the biggest research hub for Lyme Disease research, containing more than **46%** of clinical trials.

More than **17%** of clinical trials are launched in Slovenia. About **9%** are launched in France. Together, European countries make more than **47%** of clinical trials.

Other world regions together account for less than **7%** of clinical trials.

## Billionaires affected by Lyme disease



**360+**  
*Billionaires  
have Lyme disease*

Over **360+** billionaires are affected by Lyme disease. This significant figure underscores the widespread impact of the disease across various demographics, highlighting the need for continued awareness, research, and support for those affected in high-profile spheres.



## Involvement of Celebrities in Lyme Awareness



**Karen Allen**



**Christy Turlington  
Burns**



**Amy Tan**



**Debbie Gibson**



**Alec Baldwin**



**Ben Stiller**



**Daryl Hall**



**Jordan Fisher**



**Marla Maples**



**Lauren Lovejoy**



**Ally Sheedy**



**Rebecca Wells**



**Dana Parish**



**Kelly Osbourne**




**Jamie-Lynn Sigler**



**Daryl Hannah**



**Ramona Singer**



**Parker Posey**



**Ashley Olsen**



**Debbie Harry**



**Kathleen Hanna**



**Scott Jurek**




**Katina Makris**




**Bella Hadid**

## Market at a Glance: Lyme Clinics

Distribution of Clinics by Country, %



Distribution of Lyme Disease Clinics by Type, %



The Global Lyme Disease Diagnostic, Treatment, and Prevention Market is segmented here based on countries and categories.

The **majority** of companies that offer services against Lyme are located in the **UK** and the **USA**, the home of **32%** and **29%** of the whole range of companies analysed in the report. The USA is distantly followed by the Germany with **13%**, Canada with **6%**, and other countries, which together host remaining **20%** of the world's Lyme Disease clinics.

# Lyme Industry Framework

## Treatment

Lyme Treatment

Gene and Cell Therapy

Small Molecules

Drug Delivery Systems

Supplements

Formulations (drugs)

Probiotics

Natural Products

## Clinics

Lyme Screening and Management

Clinical Trials Management

Nursing

Rehabilitation

Patient Monitoring and Management

EHR

Residential, Home and Elder Care

Assisted living

## MedTech

Medical Supplies and Equipment, Raw Material

Devices (diagnostics, therapy)

Medical Suppliers

Diagnostics, Tests and Labs

E-Pharmacy

Medical Devices (Artificial Organs)

Imaging

Organ Engineering

Biologics ( RNA, vaccines, AB)

Genomics and Genetics

AI for Drug Discovery

CRO

AI for Diagnostics (Ommic, Imaging)

Physiological, Systemic and Digital Biomarkers

## Scientific innovation

Insurance

Contract Manufacturing

Clinical Data Storage and Management

Education platforms

Media

Non-Profits

## Civil services

Adults in Lyme

Healthy Lifestyle

Autism in Lyme


Alzheimer in Lyme

Pets in Lyme

Skin and Connective Tissues

## Prevention and Care

## Lyme Disease Diagnostic Market Size



The Compound Annual Growth Rate (CAGR) for this period is **6.5%**. This growth is attributed to various factors such as increased awareness and reporting of Lyme disease cases, advancements in diagnostic technologies, and continuous investment in research and development for more accurate and efficient diagnostic tools for Lyme disease detection.

The market is projected to expand steadily **from USD 2.52 Billion in 2022 to USD 4 Billion in 2032**, highlighting the increasing demand for advanced diagnostic tools in detecting Lyme disease, which would lead to earlier diagnosis and better management of the condition.

# Prospective Treatments for Lyme Disease

## Hyperbaric Chamber




**Currently, the most common treatment for Lyme disease is a course of antibiotics, most effective in the early stages of the disease.** In later stages, intravenous antibiotics may be necessary. In some cases, people with persistent symptoms after treatment, a condition called post-treatment Lyme disease syndrome, may require additional therapy or supportive care. Pain relievers and anti-inflammatory drugs may also be used to manage symptoms.

## Stem Cells Treatments



**Lyme disease management**, should be placing a focal point on comprehensive treatments and weaving a comprehensive and evolving narrative. Moving beyond conventional antibiotics, the treatment need to encompass diverse modalities, including herbal remedies, mind-body interventions, **stem cell therapy**, **hypoxia therapy**, and **hyperbaric chambers** and so on. **This holistic lens emphasizes** the intricate interconnectedness of mental and physical well-being, recognizing the nuanced nature of Lyme disease care.

## Lyme Disease Treatment Market Size



The global Lyme disease treatment market is expected to witness substantial growth, climbing from **USD 805.00 Million in 2022** to **USD 1,820.09 Million in 2032**, representing a robust Compound Annual Growth Rate (CAGR) of approximately **8.5%**. This growth is driven by rising reported cases of Lyme disease, increased investments in healthcare by major companies, advancements in healthcare facilities, and the development of more accurate diagnostic methods like Spectroscopic testing, particularly Raman spectroscopy testing. These factors collectively contribute to the steady expansion of the market, indicating a growing demand for enhanced treatment and diagnostics for Lyme disease.

## Conclusions

- The impact of the Lyme pandemic on public health is a multifaceted challenge that demands proactive measures. From increased disease burden to diagnostic and treatment complexities, addressing these issues requires a concerted effort from healthcare professionals, policymakers, and the public alike. By fostering awareness, enhancing research, and fortifying healthcare systems, we can collectively mitigate the adverse effects of Lyme disease on global public health.
- In the realm of Lyme disease, complexities and challenges are emerging, echoing the dynamic landscape observed in other areas of healthcare. Unlike the well-defined monopolies dominating certain markets, Lyme disease involves a diverse range of stakeholders, including pharmaceutical companies, diagnostic and treatment innovators.
- As we navigate the intricacies of Lyme disease, considering its links to persistent inflammation, compromised immune function, and potential associations with age-related diseases, the focus must be on fostering innovation and research. Unlike concentrated dominance seen in some sectors, the Lyme landscape encourages diverse entities to contribute to diagnostics, treatments, and preventive strategies.
- While there may not be giants monopolizing the Lyme market, as observed in certain industries, the collective efforts of various players—pharmaceutical companies, researchers, and healthcare providers—become the driving force.

# Longevity Industry Analytics: Value Proposition

Visit Website



Longevity Industry Analytics is the only specialised analytics agency that focuses exclusively on the emerging Longevity Industry. We are recognised internationally as the premier analytics agency for advanced data analysis, industry reports, and next-generation infographics on ageing and Longevity.

## Longevity Industry Analytics focuses on three key activities:

### Providing Commercial Services




Conducting customised case studies, research, and analytics for internal (organisational) use, tailored to the precise needs of specific clients.

### Preparing Open-Access Reports

Producing regular open-access and proprietary analytical case studies on the emerging topics and trends in the Longevity Industry.

### Building Big Data Analytics Platforms

Offering customised analysis using specialised interactive industry and technology databases, IT-platforms, and Big Data Analytics Dashboards.



Website: [www.aginganalytics.com](http://www.aginganalytics.com)





**E-mail: [info@aginganalytics.com](mailto:info@aginganalytics.com)**

**Website: [www.aginganalytics.com](http://www.aginganalytics.com)**

**Longevity Industry Analytics (LIA) Disclaimer.**

The information and opinions in this report were prepared by Longevity Industry Analytics. The information herein is believed by LIA to be reliable but LIA makes no representation as to the accuracy or completeness of such information. There is no guarantee that the views and opinions expressed in this communication will come to pass. LIA may provide, may have provided, or may seek to provide advisory services to one or more companies mentioned herein. In addition, employees of LIA may have purchased or may purchase securities in one or more companies mentioned in this report. Opinions, estimates, and analyses in this report constitute the current judgment of the author as of the date of this report. They do not necessarily reflect the opinions of LIA and are subject to change without notice. LIA has no obligation to update, modify, or amend this report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, estimate, forecast, or analysis set forth herein, changes or subsequently becomes inaccurate. This report is provided for informational purposes only. It is not to be construed as an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular trading strategy in any jurisdiction.